Untitled

Rosenstein, Leslie D.

doi:10.1023/a:1025628925796

Cited by 54 publications

(3 citation statements)

References 200 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Beeston 5 confi rms, based on an extensive review of many research studies, 10,[41][42][43] that the treatment and handling of depression may be the singular most important factor in the prevention of suicide in elderly individuals. Although there is a prejudice according to which elderly people are naturally depressed because of their age, depression is not a normal fact of ageing.…”

Section: 43mentioning

confidence: 99%

Suicídio entre pessoas idosas: revisão da literatura

Minayo

Cavalcante

2010

Rev. Saúde Pública

View full text Add to dashboard Cite

A literature review was carried out focusing on the main factors associated with suicidal ideation, attempts and completed suicide in elders. The following databases were searched: MEDLINE, PsychINFO, SciELO and Biblioteca Virtual em Violência e Saúde da BIREME (BIREME's Violence and Health Virtual Library), referring to the period from 1980 to 2008. Fifty-two references were selected and analyzed. They showed a strong relationship among suicide ideation, attempt and completion in elderly individuals, which results from the interaction of complex physical, mental, neurobiological and social factors. Suicide associated with depression in the elderly can be prevented, provided the person is properly treated. In Brazil, it is necessary to invest in research, given the persistent increase in suicide rates among aged people, especially among males.

show abstract

Section: 43mentioning

confidence: 99%

Suicídio entre pessoas idosas: revisão da literatura

Minayo

Cavalcante

2010

Rev. Saúde Pública

View full text Add to dashboard Cite

show abstract

“…This progressive neurodegenerative disease affects approximately 24 million individuals worldwide, with one new case detected every seven seconds [2]. AD patients exhibit the following symptoms: decline in executive functions, memory impairment, visuospatial and language difficulties, and behavioral disturbances [3]. …”

Section: Introductionmentioning

confidence: 99%

Predictors of long-term cognitive outcome in Alzheimer's disease

Wattmo

Wallin

Londos

et al. 2011

Alzheimers Res Ther

122

View full text Add to dashboard Cite

IntroductionThe objective of this study was to describe the longitudinal cognitive outcome in Alzheimer's disease (AD) and analyze factors that affect the outcome, including the impact of different cholinesterase inhibitors (ChEI).MethodsIn an open, three-year, nonrandomized, prospective, multicenter study, 843 patients were treated with donepezil, rivastigmine, or galantamine in a routine clinical setting. At baseline and every six months, patients were assessed using several rating scales, including the Mini-Mental State Examination (MMSE) and the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and the dose of ChEI was recorded. Sociodemographic and clinical characteristics were investigated. The relationships of these predictors with longitudinal cognitive ability were analyzed using mixed-effects models.ResultsSlower long-term cognitive decline was associated with a higher cognitive ability at baseline or a lower level of education. The improvement in cognitive response after six months of ChEI therapy and a more positive longitudinal outcome were related to a higher mean dose of ChEI, nonsteroidal anti-inflammatory drug (NSAID)/acetylsalicylic acid usage, male gender, older age, and absence of the apolipoprotein E (APOE) ε4 allele. More severe cognitive impairment at baseline also predicted an improved response to ChEI treatment after six months. The type of ChEI agent did not influence the short-term response or the long-term outcome.ConclusionsIn this three-year AD study performed in a routine clinical practice, the response to ChEI treatment and longitudinal cognitive outcome were better in males, older individuals, non-carriers of the APOE ε4 allele, patients treated with NSAIDs/acetylsalicylic acid, and those receiving a higher dose of ChEI, regardless of the drug agent.

show abstract

“…Alzheimer’s disease (AD) is an insidiously progressive neurodegenerative disorder characterized by multiple cognitive deficiencies, including increasing impairment in memory, orientation, language and executive ability, as well as deterioration of functional capacity [1]. Currently, the main treatment for mild-to-moderate AD is acetylcholinesterase inhibitors (ChEI), which have shown positive symptomatic effects on cognition and function compared with a placebo in randomized clinical trials [2].…”

Section: Introductionmentioning

confidence: 99%

Progression of mild Alzheimer’s disease: knowledge and prediction models required for future treatment strategies

Wattmo

Wallin

Minthon

2013

Alzheimers Res Ther

View full text Add to dashboard Cite

IntroductionKnowledge of longitudinal progression in mild Alzheimer’s disease (AD) is required for the evaluation of disease-modifying therapies. Our aim was to observe the effects of long-term cholinesterase inhibitor (ChEI) therapy in mild AD patients in a routine clinical setting.MethodsThis was a prospective, open-label, non-randomized, multicenter study of ChEI treatment (donepezil, rivastigmine or galantamine) conducted during clinical practice. The 734 mild AD patients (Mini-Mental State Examination (MMSE) score 20 to 26) were assessed at baseline and then semi-annually over three years. Outcome measures included the MMSE, Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog), Clinician’s Interview-Based Impression of Change (CIBIC) and Instrumental Activities of Daily Living (IADL) scale.ResultsAfter three years of ChEI therapy, 31% (MMSE) and 33% (ADAS-cog) of the patients showed improved/unchanged cognitive ability, 33% showed improved/unchanged global performance and 14% showed improved/unchanged IADL capacity. Higher mean dose of ChEI and lower educational level were both predictors of more positive longitudinal cognitive and functional outcomes. Older participants and those with a better IADL score at baseline exhibited a slower rate of cognitive decline, whereas younger participants and those with higher cognitive status showed more preserved IADL ability over time. Gender and apolipoprotein E (APOE) genotype showed inconsistent results. Prediction models using the abovementioned scales are presented.ConclusionsIn naturalistic mild AD patients, a marked deterioration in IADL compared with cognitive and global long-term outcomes was observed, indicating the importance of functional assessments during the early stages of the disease. The participants’ time on ChEI treatment before inclusion in studies of new therapies might affect their rate of decline and thus the comparisons of changes in scores between various studies. An increased understanding of expected disease progression in different domains and potential predictors of disease progression is essential for assessment of future therapies in AD.

show abstract

Untitled

Cited by 54 publications

References 200 publications

Suicídio entre pessoas idosas: revisão da literatura

Suicídio entre pessoas idosas: revisão da literatura

Predictors of long-term cognitive outcome in Alzheimer's disease

Progression of mild Alzheimer’s disease: knowledge and prediction models required for future treatment strategies

Contact Info

Product

Resources

About